Barclays Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00

Moderna (NASDAQ:MRNA) had its price objective lowered by analysts at Barclays from $31.00 to $25.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Barclays‘s target price indicates a potential upside of 5.42% from the company’s previous close.

MRNA has been the subject of a number of other reports. Cowen started coverage on shares of Moderna in a report on Sunday, July 13th. They issued a “hold” rating for the company. Leerink Partners decreased their price objective on Moderna from $18.00 to $15.00 and set an “underperform” rating for the company in a research report on Friday, August 22nd. Evercore ISI set a $32.00 price target on shares of Moderna in a research report on Friday, August 1st. JPMorgan Chase & Co. dropped their target price on Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a report on Thursday, October 23rd. Finally, Bank of America decreased their target price on shares of Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research note on Tuesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have given a Hold rating and five have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $36.43.

Moderna Stock Down 2.5%

Shares of Moderna stock traded down $0.62 on Friday, hitting $23.71. The company’s stock had a trading volume of 5,211,627 shares, compared to its average volume of 10,953,079. The firm has a fifty day moving average price of $25.80 and a 200-day moving average price of $27.13. The company has a market capitalization of $9.26 billion, a P/E ratio of -3.15 and a beta of 2.02. Moderna has a 52-week low of $23.04 and a 52-week high of $50.90.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.15) by $1.64. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $893.29 million. During the same quarter last year, the firm posted $0.03 earnings per share. The business’s quarterly revenue was down 45.4% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. As a group, analysts expect that Moderna will post -9.61 earnings per share for the current year.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. S Bank Fund Management Ltd bought a new position in Moderna during the first quarter valued at approximately $25,000. Rothschild Investment LLC boosted its position in Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares during the period. TD Private Client Wealth LLC increased its holdings in shares of Moderna by 348.8% in the second quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after buying an additional 743 shares during the period. Atlantic Union Bankshares Corp bought a new stake in shares of Moderna in the 2nd quarter valued at about $26,000. Finally, SVB Wealth LLC bought a new position in Moderna during the 1st quarter worth approximately $28,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.